Material and methods Chronic urticaria (CU) is a common skin disease affecting around 0.5 to 1% of the general population [1]. The guidelines for therapeutic management, updated in 2018, recommend omalizumab (Xolair®), the first anti-IgE biotherapy, as third-line therapy, after second-generation (2G) anti-histamines (anti-H1), whether or not at increased dosage, but with restricted access to specialist physicians in France [2]. There are few studies on CU management in primary care. This disease may cause difficulties for general practitioners (GPs) in diagnosis and therapy, especially since the prescription of corticosteroids increases the risk of chronicity and relapses [3]. We aimed to assess the management of CU by GPs in the North of France using an anonymous survey in order to better understand and improve the healthcare pathway in primary care.